Likewise, limited evidence exists recommending the clinical use of dipeptidyl peptidase-4 (DPP-4) inhibitors and endothelin receptor antagonists in the treatment of hypertensive nephropathy, although there is good evidence in diabetic kidney disease. This evidence concerns the gene DPP4 and diabetic kidney disease.